FCM
AMPH icon

Fourpath Capital Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Fourpath Capital Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20
Closed -$971 – 250
2024
Q3 		$971 Buy
+20
New +$878 ﹤0.01% 712

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Fourpath Capital Management's AMPH Position: Q4 2024 in Review

Fourpath Capital Management sold out of Amphastar Pharmaceuticals (AMPH) in Q4 2024, closing a stake of 20 shares — an estimated $971 sold.

Fourpath Capital Management first reported a position in AMPH in Q3 2024 and held it in 1 quarter. The position peaked at $971 in Q3 2024. 263 funds tracked by Wall St. Rank hold AMPH as of Q4 2024.

  • Fourpath Capital Management reported no remaining Amphastar Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Fourpath Capital Management sold 20 Amphastar Pharmaceuticals shares in Q4 2024, an estimated $971.
  • Fourpath Capital Management first reported a position in Amphastar Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Fourpath Capital Management's Amphastar Pharmaceuticals position peaked at $971 in Q3 2024.
  • 263 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q4 2024.

Based on Fourpath Capital Management's 13F filing for Q4 2024, filed 24 Jan 2025.